Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emanuela Scarpi

Showing results (181-190 of 216) with videos related to

Pageof 22
Sort By:
Oncotarget|February 20, 2016
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR groupAndrea Casadei Gardini, Emanuela Scarpi, Giorgia Marisi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 6, 2020
Early Gastric Cancer: identification of molecular markers able to distinguish submucosa-penetrating lesions with different prognosisChiara Molinari, Gianluca Tedaldi, Francesca Rebuzzi, et al.
Vaccines|July 27, 2022
Stability Program in Dendritic Cell Vaccines: A "Real-World" Experience in the Immuno-Gene Therapy Factory of Romagna Cancer CenterElena Pancisi, Anna Maria Granato, Emanuela Scarpi, et al.
Journal of Translational Medicine|June 4, 2013
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patientsLaura Ridolfi, Massimiliano Petrini, Anna Maria Granato, et al.
JAMA Network Open|July 14, 2026
Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical CancerAlberto Farolfi, Chiara Casadei, Emanuela Scarpi, et al.
Scientific Reports|October 24, 2020
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective studyAlberto Farolfi, Emanuela Scarpi, Filippo Greco, et al.
Expert Opinion on Pharmacotherapy|October 30, 2015
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenibAndrea Casadei Gardini, Giorgia Marisi, Emanuela Scarpi, et al.
Targeted Oncology|June 28, 2018
Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)Alberto Farolfi, Micaela Petrone, Emanuela Scarpi, et al.
International Journal of Cancer|October 4, 2021
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patientsVincenza Conteduca, Emanuela Scarpi, Daniel Wetterskog, et al.
The Oncologist|May 16, 2025
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancerVincenza Conteduca, Emanuela Scarpi, Alice Rossi, et al.
Pageof 22

Showing results (181-190 of 216) with videos related to

Sort By:
Pageof 22
Oncotarget|February 20, 2016
Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR groupAndrea Casadei Gardini, Emanuela Scarpi, Giorgia Marisi, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|November 6, 2020
Early Gastric Cancer: identification of molecular markers able to distinguish submucosa-penetrating lesions with different prognosisChiara Molinari, Gianluca Tedaldi, Francesca Rebuzzi, et al.
Vaccines|July 27, 2022
Stability Program in Dendritic Cell Vaccines: A "Real-World" Experience in the Immuno-Gene Therapy Factory of Romagna Cancer CenterElena Pancisi, Anna Maria Granato, Emanuela Scarpi, et al.
Journal of Translational Medicine|June 4, 2013
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patientsLaura Ridolfi, Massimiliano Petrini, Anna Maria Granato, et al.
JAMA Network Open|July 14, 2026
Bevacizumab and Platinum Choice in Pembrolizumab-Treated Advanced Cervical CancerAlberto Farolfi, Chiara Casadei, Emanuela Scarpi, et al.
Scientific Reports|October 24, 2020
Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective studyAlberto Farolfi, Emanuela Scarpi, Filippo Greco, et al.
Expert Opinion on Pharmacotherapy|October 30, 2015
Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenibAndrea Casadei Gardini, Giorgia Marisi, Emanuela Scarpi, et al.
Targeted Oncology|June 28, 2018
Inflammatory Indexes as Prognostic and Predictive Factors in Ovarian Cancer Treated with Chemotherapy Alone or Together with Bevacizumab. A Multicenter, Retrospective Analysis by the MITO Group (MITO 24)Alberto Farolfi, Micaela Petrone, Emanuela Scarpi, et al.
International Journal of Cancer|October 4, 2021
Plasma tumor DNA is associated with increased risk of venous thromboembolism in metastatic castration-resistant cancer patientsVincenza Conteduca, Emanuela Scarpi, Daniel Wetterskog, et al.
The Oncologist|May 16, 2025
Changing metastatic patterns associate with dynamics of circulating tumor DNA in metastatic castration-resistant prostate cancerVincenza Conteduca, Emanuela Scarpi, Alice Rossi, et al.
Pageof 22